A study compared the concordance between participant and clinician assessment of eligibility for rosuvastatin 5 mg using an at-home web-based application.
In a pooled analysis of six cohort studies, higher sodium and lower potassium intakes measured by multiple 24-h urine samples were associated with higher CV risk in a dose-response manner.
Functional iron deficiency is a relevant risk factor for CVD and mortality in the general population according to the authors of a study that investigated the relationship between iron deficiency and incident CVD and mortality.
Cumulative LDL-c and time-weighted average LDL-c during young adulthood and middle age (18-60 years) are associated with risk of incident CHD, independent of midlife LDL-c, in a cohort study of 18,288 participants.
A cost-effectiveness study suggests that population genomic screening for FH in young adults could be cost-effective from a healthcare perspective and cost-saving from a societal perspective at testing costs that are feasible.
Watch a video by prof. Banach, who gives an overview of the key messages in the new Polish lipid guidelines.
The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.
AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.
AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.
AHA 2021 This analysis of the EMPEROR-Preserved trail showed that empagliflozin reduced the primary endpoint of time to first event of CV death or HF hospitalization by 17%, compared to placebo, in HF patients with LVEF ≥50%.
AHA 2021 It is not clear yet what the effect of aspirin is on the risk of dementia in patients with T2DM. Prof. Armitage presents a study in which this was investigated using data of the ASCEND trial.
AHA 2021 Using data of the ASCEND trial, this study showed that there was no significant effect of aspirin on dementia outcomes compared to placebo in patients with T2DM.